A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.

被引：0
|
作者：
Kelly, William Kevin
Hussain, Arif
Saraiya, Biren
Thanigaimani, Pradeep
Sun, Furong
Seebach, Frank A.
Lowy, Israel
Sandigursky, Sabina
Miller, Elizabeth
机构：
[1] Thomas Jefferson Univ, Philadelphia, PA USA
[2] Univ Maryland, Med Ctr, Baltimore, MD USA
[3] Rutgers State Univ, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA
[4] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS284
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [32] A phase 1 study of AMG 509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Danila, Daniel Costin
    Waterhouse, David Michael
    Appleman, Leonard Joseph
    Pook, David William
    Matsubara, Nobuaki
    Dorff, Tanya B.
    Lee, Jae-Lyun
    Armstrong, Andrew J.
    Kim, Miso
    Horvath, Lisa
    Sumey, Christopher Joseph
    Cooner, Freda
    Salvati, Mark
    Stieglmaier, Julia
    Kelly, William Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [33] Docetaxel and curcuminoids combination in patients with castration-resistant prostate cancer: A phase II study
    Mahammedi, H.
    Pouget, M.
    Planchat, E.
    Cure, H.
    Durando, X.
    Van-Praagh, I.
    Savareux, L.
    Abrial, C.
    Chollet, P.
    Eymard, J. C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S696 - S696
  • [34] Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC).
    Laccetti, Andrew Leonard
    Chatta, Gurkamal S.
    Iannotti, Nicholas
    Kyriakopoulos, Christos
    Villaluna, Karen
    Le Moigne, Ronan
    Cesano, Alessandra
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [35] A phase 2 study of cabozantinib and nivolumab in metastatic castration-resistant prostate cancer (CANOPY)
    Chen, Yu-Wei
    Liu, Lin
    Pu, Minya
    Pena, Samuel
    Qin, Qian
    Zhang, Tian
    Emamekhoo, Hamid
    Lang, Joshua Michael
    Patnaik, Akash
    McKkay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS239 - TPS239
  • [36] Phase I study of a novel S1P inhibitor, NOX66, in combination with radiotherapy in patients with metastatic castration-resistant prostate cancer.
    de Souza, Paul L.
    Capp, Anne Louise
    Chikhladze, Nana
    Mezvrishvili, Zaza
    Messina, Marinella
    Mautner, Gisela
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] Initial phase II experience of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Slovin, S. F.
    Beer, T. M.
    Higano, C. S.
    Tejwani, S.
    Hamid, O.
    Picus, J.
    Harzstark, A.
    Scher, H. I.
    Lan, Z.
    Lowy, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [38] Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
    Kongsted, Per
    Borch, Troels Holz
    Ellebaek, Eva
    Iversen, Trine Zeeberg
    Andersen, Rikke
    Met, Ozcan
    Hansen, Morten
    Lindberg, Henriette
    Sengelov, Lisa
    Svane, Inge Marie
    CYTOTHERAPY, 2017, 19 (04) : 500 - 513
  • [39] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC).
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] A phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)
    Choudhury, Atish Dipankar
    Xie, Wanling
    Tewari, Alok
    Miyamoto, David Tomoaki
    Kochupurakkal, Bose
    Ellis, Leigh
    Bandel, Matthew
    Leisner, Claire
    Shapiro, Geoffrey
    D'Andrea, Alan D.
    Van Allen, Eliezer Mendel
    Freedman, Matthew
    Brown, Myles
    Taplin, Mary-Ellen
    Beltran, Himisha
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345